GLP-1 RAs have consistently been shown to reduce the risk of major cardiovascular and cerebrovascular events, which may in turn translate into lower risk of dementia.22 23 Specifically, in the EXSCEL trial, exenatide reduced the occurrence of death caused by a composite of vascular events (cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke),22 while SUSTAIN 6 and PIONEER 6 trials found that semaglutide reduced the incidence of major cardiovascular events in patients with T2D.23 This evidence concerns the gene GLP1R and type 2 diabetes mellitus.